Original Research Article

Prevalence of viral (HBV, HCV and HIV) co-infections among apparently healthy blood donors in Ranchi, Jharkhand, India

Sushma Kumari1*, Asha Kiran2, Ritesh Kumar3, Ramesh K. Shrivastava4

1Department of Blood Bank, Rajendra Institute of Medical Sciences, Ranchi- 834009, Jharkhand, India
2Department of Preventive and Social Medicine, Rajendra Institute of Medical Sciences, Ranchi - 834009, Jharkhand, India
3Department of Pathology, Alam Fortis Escorts Hospital and Research Center, Ranchi - 834009, Jharkhand, India
4Department of Blood Bank and Pathology, Rajendra Institute of Medical Sciences, Ranchi - 834009, Jharkhand, India

Received: 06 April 2017
Accepted: 03 May 2017

*Correspondence:
Dr. Sushma Kumari,
E-mail: ksushmaxyz@rediffmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Apparently healthy blood donors may carry double viral co-infections that might be more fatal than viral mono-infection for the donor himself as well as recipient later on.

Methods: All blood samples were screened for HIV-I and II (4th generation kit), HBV and HCV (3rd generation kit) by using chemiluminescence technique (Manufacturer- Abbott, Model-Architect i 1000SR).

Results: On screening of 41307 blood units, 829 (2.0%) donors were found positive for one of the viral infection (HBV, HCV and HIV). Highest prevalence was for HBV (417 donors- 1.0%) followed by HCV (324 donors- 0.78 %) and HIV (88 donors- 0.21 %).

Conclusions: Apparently healthy blood donors might carry, life threatening, double viral co-infections in their blood. Failure to diagnose and treat co-infection at an early stage results in serious complications and sequelae. For safe blood transfusion all blood units should be tested for compatibility and TTI’s with reduction in unnecessary blood transfusion.

Keywords: Hepatitis B virus and hepatitis C virus, Human immunodeficiency virus, Transfusion transmitted viral co-infections

INTRODUCTION

The goal of any transfusion service must be to provide adequate and safe, blood and blood products to the recipients. With every one unit of blood transfusion there is 1% chance of transfusion related complications including Transfusion transmitted infections.1 Preventing transmission of transfusion transmitted infections through blood transfusion presents one of the greatest challenges of transfusion medicine.2 The Drug and Cosmetic Act, 1945 (amended from time to time), all the blood donations are to be screened against the five major infections namely HIV I and II, HBsAg, HCV, syphilis and malaria.3-4 NACO recommended 3rd or 4th generation ELISA HIV I and II test kits which are 100% sensitive should be preferred for use at blood banks for screening of donated blood.5 Blood transfusion departments not only screen TTI but also give clue about the prevalence of these infections in healthy populations.6 Most of the studies worldwide show majority of the blood donors are associated with viral (HBV, HCV and HIV) mono-infection but few studies also tell the truth of double viral infections.
co-infections among apparently healthy blood donors. The HIV-HBV or HIV-HCV co-infection has been reported worldwide, and some studies provide evidence that the rate of HBV is higher than that of HCV in HIV infected patients. Conflicting results are reported in some studies. Hepatic diseases are one of the leading causes of morbidity and mortality in co-infected patients. The aim of our present study was to know the prevalence of double viral co-infections among apparently healthy donors in Ranchi, Jharkhand, India, and to heighten the awareness of the infectious complications of blood transfusion.

**METHODS**

This was a retrospective study done at blood bank, RIMS, Ranchi from 17th July 2015 to 16th January 2017 (18 months study). All blood samples were screened for HIV-I and II Ag/Ab (4th generation kit- Abbott diagnostic), HBSAg and Anti-HCV (3rd generation kit- Abbott diagnostic) by using chemiluminescence technique (Manufacturer- Abbott, Model-Architect i 1000SR). Test results were taken in relative light units (RLUs). Blood units showing result 1.0 RLU or more than It as well grey zone results (0.90 to 0.99) were considered as positive for corresponding infection.

**RESULTS**

From 17th July 2015 to 16th January 2017 a total of 41307 blood units were screened in which 829 (2.0%) donors were found positive for one of the viral infections (HBV, HCV and HIV) (Table 1).

Highest prevalence was for HBV (417 donors- 1.0%) followed by HCV (324 donors-0.78 %) and HIV (88 donors- 0.21%). 05 donors showed double viral co-infections with HBV and HCV and 03 donors showed double viral co-infections with HBV and HIV (Table 2). HCV and HIV co-infections were not found in present study. Table 3 and Table 4 showed test results in relative light units (RLUs) of double viral co-infections of HBV and HCV as well as HBV and HIV respectively.

<table>
<thead>
<tr>
<th>Time period</th>
<th>Total no. of blood units screened</th>
<th>Total no. of HBV mono-infection</th>
<th>% of Total no. of HBV mono-infection</th>
<th>Total no. of HCV mono-infection</th>
<th>% of Total no. of HCV mono-infection</th>
<th>Total no. of HIV mono-infection</th>
<th>% of Total no. of HIV mono-infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>17 July 2015-31 December 2015</td>
<td>12552</td>
<td>122</td>
<td>0.29</td>
<td>88</td>
<td>0.21</td>
<td>33</td>
<td>0.07</td>
</tr>
<tr>
<td>01 January 2016-31 December 2016</td>
<td>27790</td>
<td>282</td>
<td>0.68</td>
<td>222</td>
<td>0.53</td>
<td>53</td>
<td>0.12</td>
</tr>
<tr>
<td>01 January 2017-16 January 2017</td>
<td>965</td>
<td>13</td>
<td>0.03</td>
<td>14</td>
<td>0.03</td>
<td>02</td>
<td>0.0048</td>
</tr>
<tr>
<td>Grand total</td>
<td>41307</td>
<td>417</td>
<td>1.0</td>
<td>324</td>
<td>0.78</td>
<td>88</td>
<td>0.21</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time Period</th>
<th>Total no. of HBS and HCV co-infections</th>
<th>% of total no. of HBS and HCV co-infections</th>
<th>Total no. of HBS and HIV co-infections</th>
<th>% of total no. of HBS and HIV co-infections</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 January 2016-31 December 2016</td>
<td>04</td>
<td>0.0096</td>
<td>03</td>
<td>0.0072</td>
</tr>
<tr>
<td>01 January 2017-16 January 2017</td>
<td>01</td>
<td>0.0024</td>
<td>Zero</td>
<td>Zero</td>
</tr>
<tr>
<td>Grand Total</td>
<td>05</td>
<td>0.0121</td>
<td>03</td>
<td>0.0072</td>
</tr>
</tbody>
</table>
Table 3: Test results of blood units having double viral co-infections of HBV and HCV in relative light units (RLUs).

<table>
<thead>
<tr>
<th>Date</th>
<th>Annual bag no.</th>
<th>Age</th>
<th>Sex</th>
<th>Result of HBSAgQ2 in RLUs</th>
<th>Result of Anti-HCV in RLUs</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 May 2016</td>
<td>9343</td>
<td>26</td>
<td>Male</td>
<td>4153.45</td>
<td>0.91</td>
</tr>
<tr>
<td>02 July 2016</td>
<td>13506</td>
<td>39</td>
<td>Male</td>
<td>1148.07</td>
<td>1.79</td>
</tr>
<tr>
<td>28 August 2016</td>
<td>17997</td>
<td>35</td>
<td>Male</td>
<td>2648.79</td>
<td>2.41</td>
</tr>
<tr>
<td>30 December 2016</td>
<td>27709</td>
<td>38</td>
<td>Male</td>
<td>5149.37</td>
<td>9.29</td>
</tr>
<tr>
<td>05 January 2017</td>
<td>243</td>
<td>36</td>
<td>Male</td>
<td>5846.20</td>
<td>7.25</td>
</tr>
</tbody>
</table>

Table 4: Test results of blood units having double viral co-infections of HBV and HIV in relative light units (RLUs).

<table>
<thead>
<tr>
<th>Date</th>
<th>Annual bag no.</th>
<th>Age</th>
<th>Sex</th>
<th>Result of HBS AgQ2 in RLUs</th>
<th>Result of HIV Ag/Ab in RLUs</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 February 2016</td>
<td>2699</td>
<td>37</td>
<td>Male</td>
<td>1096.18</td>
<td>582.18</td>
</tr>
<tr>
<td>12 February 2016</td>
<td>2763</td>
<td>29</td>
<td>Male</td>
<td>1.27</td>
<td>3.25</td>
</tr>
<tr>
<td>20 February 2016</td>
<td>3207</td>
<td>36</td>
<td>Male</td>
<td>2821.39</td>
<td>451.45</td>
</tr>
</tbody>
</table>

DISCUSSION

Human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) are the three most common chronic viral infections documented worldwide.\(^{15,16}\) It is estimated that more than 33 million people are infected with HIV worldwide.\(^{17}\) Approximately 20% of HIV-positive patients who acquire acute HBV infection develop chronic HBV infection compared to only 5% of HIV-negative persons.\(^{18}\) It is observed that, those HIV infected individuals who are co-infected with hepatitis viruses display rapid progression to severe liver disease and have an increased risk of hepatotoxicity associated with antiretroviral therapy.\(^{19}\) HIV is responsible for about 40 million chronic infections while hepatitis C and hepatitis B cause 130 million and 370 million chronic infections respectively.\(^{13}\) Failure to diagnose and treat co-infection at an early stage results in serious complications and sequelae.\(^{7}\) Prevalence of HBV and HCV co-infections in the different geographical area around the world displays great variation.\(^{7}\) In US and Europe, HIV and HBV co-infection was reported to be 6 to 14 % while reports for HIV and HCV varied in the range of 25 to 50 % (9, 19). In India the overall rate of infection with HBV and HCV varies from 1-6%.\(^{20,22}\) The rate of HBV and HCV co-infection in HIV patients has been reported in few studies in Nepal.\(^{16,23}\) Ghimire P et al found the co-prevalence of HBV/HIV in Nepal to be 0.033% which was higher than the present study.\(^{18}\) Karki S et al reported the co-infection rate of 10.8% for HCV and HIV in the blood donors.\(^{23}\) No study pertaining to incidence of co-infections with these viruses has been done in Jharkhand till date. The HIV-HCV co-infection was not found in present study whereas this study showed HIV-HBV co-infection rate of (0.0072%). Co-infection with the three viruses increase the risk of acute and chronic liver insufficiency, cirrhosis, hepatic failure and mortalities in comparison to when a person is infected with only one of these viruses.\(^{7}\) HBV co-infections in female patients were more prevalent than in their male counterpart.\(^{7}\) But in present study all the HBV co-infected individuals were male and the commonest age group affected was 30 to 40 years of age. People with unsafe sexual relationships and addiction to drugs injection should always be careful as the chances of virus getting transmitted are high among them and the knowledge of co-infection in patients of HIV is vital since these patients, as they live longer on antiretroviral treatment will also need to be managed for their co-infection with HBV or HCV.\(^{7}\) The replication of HBV and HCV in HIV patients should be actively monitored while receiving antiviral therapy and this monitoring system should be made a part of clinical care.\(^{24}\) Compared to HIV-mono-infected patients, those with HIV-hepatitis co-infection are at increased hazard of developing liver enzyme elevations on antiretroviral therapy.\(^{25}\) Hepatitis viruses in HIV may lead to faster progression to liver cirrhosis and a higher risk of antiretroviral therapy induced hepatotoxicity.\(^{7}\)

ACKNOWLEDGEMENTS

Authors are thankful to the technical staff Prasen Prasad, Blood Bank, RIMS, Ranchi for his sincere help to collect the data.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES


